Applications to Gynecological Cancers

  • Anthony W. Fyles
  • Michael Milosevic
  • Amit Oza
Part of the Medical Radiology book series (MEDRAD)


Epidermal Growth Factor Receptor Cervical Cancer Endometrial Cancer Clin Oncol Human Papilloma Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Airley RE et al (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85–91PubMedCrossRefGoogle Scholar
  2. Bachtiary B et al (2005) Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 63:1077–1082PubMedCrossRefGoogle Scholar
  3. Baxter L, Jain R (1989) Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 37:77–104PubMedCrossRefGoogle Scholar
  4. Bergers G et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMedCrossRefGoogle Scholar
  5. Bonner J et al (2004) Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 60(Suppl): S147–S148CrossRefGoogle Scholar
  6. Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism for reoxygenation. Br J Radiol 52:650–656PubMedGoogle Scholar
  7. Brown JM (1993) SR 4233 (Tirapazamine): a new anti-cancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163–1170PubMedGoogle Scholar
  8. Burri P et al (2003) Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494–501PubMedCrossRefGoogle Scholar
  9. Bush RS et al (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37(Suppl III):302–306Google Scholar
  10. Chan P et al (2004) A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 70:295–296PubMedCrossRefGoogle Scholar
  11. Chen MD et al (1997) Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 67:131–136PubMedCrossRefGoogle Scholar
  12. Craighead PS, Pearcey R, Stuart G (2000) A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 48:791–795PubMedCrossRefGoogle Scholar
  13. Dai Y et al (2005) The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 97:96–103PubMedCrossRefGoogle Scholar
  14. Dayes IS, Abuzallouf S (2005) Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. Br J Radiol 78:777–782PubMedCrossRefGoogle Scholar
  15. De Vos FY et al (2004) Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer. Anticancer Res 24:345–348PubMedGoogle Scholar
  16. Dische S et al (1984) The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix. Br J Radiol 57:491–499CrossRefGoogle Scholar
  17. Dische S et al (1993) A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 26:93–103CrossRefGoogle Scholar
  18. DiSilvestro P, Walker J, Morrsion A (2005) A phase I/II study of radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical cancer limited to the pelvis, a Gynecologic Oncology Group study. SGO Annual Meeting, 2005, Abstract 106Google Scholar
  19. Dong J et al (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800–2810PubMedCrossRefGoogle Scholar
  20. Duenas-Gonzalez A et al (2005) Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized phase II study. Int J Radiat Oncol Biol Phys 61:817–823PubMedCrossRefGoogle Scholar
  21. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(Suppl 16):15–18PubMedGoogle Scholar
  22. Fyles A et al (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20:680–687PubMedCrossRefGoogle Scholar
  23. Gaffney DK et al (2001) Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213–1217PubMedCrossRefGoogle Scholar
  24. Gaffney DK et al (2003) Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 56:922–928PubMedCrossRefGoogle Scholar
  25. Gaffney DK et al (2005) A phase I–II study of COX-2 inhibitor, Celebrex (Celecoxib) and chemoradiation in patients with kocally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 63(Suppl 1):S93–S94CrossRefGoogle Scholar
  26. Green J et al (2005) Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev CD002225Google Scholar
  27. Grigsby PW et al (1999) Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 44:513–517PubMedCrossRefGoogle Scholar
  28. Harrison L, Blackwell K (2004) Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40PubMedCrossRefGoogle Scholar
  29. Heldin CH et al (2004) High interstitial fluid pressure: an obstacle in cancer therapy. Nat Rev Cancer 4:806–813PubMedCrossRefGoogle Scholar
  30. Henke M et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260PubMedCrossRefGoogle Scholar
  31. Hernandez P, Olivera P, Duenas-Gonzales A, Perez-Pastenes MA, Zarate A, Maldonado V, Melendez-Zajgla J. (2001) Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol. 48(6):488–492PubMedCrossRefGoogle Scholar
  32. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRefGoogle Scholar
  33. Hockel M et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMedGoogle Scholar
  34. Hockel M et al (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525–4528PubMedGoogle Scholar
  35. Hougardy BM et al (2005) Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol 6:589–598PubMedCrossRefGoogle Scholar
  36. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039–3051PubMedGoogle Scholar
  37. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658PubMedGoogle Scholar
  38. Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRefGoogle Scholar
  39. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in a antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  40. Jasas KV et al (2004) Phase II study of erlotinib (OSA-774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND 148 (Abstract). J Clin Oncol 22(Suppl):453sGoogle Scholar
  41. Keys H et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161PubMedCrossRefGoogle Scholar
  42. Kim GE et al (2004) Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10:1366–1374PubMedCrossRefGoogle Scholar
  43. Kim HJ et al (2003) High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 55:16–20PubMedCrossRefGoogle Scholar
  44. Lanciano R et al (2005) A randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group Study. J Clin Oncol 23, epubGoogle Scholar
  45. Leborgne F, Leborgne JH, Doldan R, Zubizarreta E, Ortega B, Maisonneuve J, Museti E, Hekimian L, Mezzera J (1997) Induction chemotherapy and radiotherapy of advanced cancer of the cervic: a pilot study and phase III randomized trials. Int J Radiat Oncol Biol Phys. 37(2):343–350PubMedCrossRefGoogle Scholar
  46. Lee C et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic and hypoxic conditions. Cancer Res 60:5565–5570PubMedGoogle Scholar
  47. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460PubMedCrossRefGoogle Scholar
  48. Lorvidhaya V et al (2003) Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 55:1226–1232PubMedCrossRefGoogle Scholar
  49. Lukka H, Johnston M (2004) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a metaanalysis. Clin Oncol (R Coll Radiol) 16:160–161Google Scholar
  50. Lyng H et al (2000) Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 6:1104–1112PubMedGoogle Scholar
  51. Mackay H et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526–5533PubMedCrossRefGoogle Scholar
  52. Maduro JH et al (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29:471–488PubMedCrossRefGoogle Scholar
  53. Mathur SP et al (2001) Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 46:280–287PubMedCrossRefGoogle Scholar
  54. Milosevic M et al (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61:6400–6405PubMedGoogle Scholar
  55. Mollica FR, Jain RK, Netti PA (2003) A model for temporal heterogeneities of tumor blood flow. Microvasc Res 65:56–60PubMedCrossRefGoogle Scholar
  56. Montana GS et al (2000) Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 48:1007–1013PubMedCrossRefGoogle Scholar
  57. Moore DH et al (1998) Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42:79–85PubMedCrossRefGoogle Scholar
  58. Morgan B et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRefGoogle Scholar
  59. Morris M et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143PubMedCrossRefGoogle Scholar
  60. Mundt AJ et al (2001) Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 82:333–337PubMedCrossRefGoogle Scholar
  61. Mundt AJ et al (2004) Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 92:801–805PubMedCrossRefGoogle Scholar
  62. Nordsmark M et al (2003) Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 67:35–44PubMedCrossRefGoogle Scholar
  63. Okkan S et al (1996) A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results. Br J Cancer 74(Suppl 27):S282–S286Google Scholar
  64. Onishi T, Ohishi Y, Imagawa K, Ohmoto Y, Murata K (1999) An assessment of the immunological environment based on intratumoral cytokine production in renal carcinoma. BJU Int. 83(4):488–492PubMedCrossRefGoogle Scholar
  65. Overgaard J (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509–510PubMedGoogle Scholar
  66. Overgaard J et al (1989) Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 16:1069–1072PubMedGoogle Scholar
  67. Padilla LA, Mitchell SK, Carson LF (2005) Phase I study of topotecan continuous infusion and weekly cisplatin with radiation therapy for locally advanced/recurrent cervical cancer. Proc Am Soc Clin Oncol, Abstract 5129Google Scholar
  68. Pearcey R, Brundage M. Drouin P, Jeffrey J, Johnston D, Lukka H. MacLean G, Souhami L, Stuart G, Tu D (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 20(4):891–893CrossRefGoogle Scholar
  69. Peters WA III et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613PubMedGoogle Scholar
  70. Pietras K et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929–2934PubMedGoogle Scholar
  71. Pietras K et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476–5484PubMedGoogle Scholar
  72. Pignata S et al (2000) Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol 11:455–459PubMedCrossRefGoogle Scholar
  73. Prise KM et al (2005) New insights on cell death from radiation exposure. Lancet Oncol 6:520–528PubMedCrossRefGoogle Scholar
  74. Rakovitch E et al (1997) Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 38:979–987PubMedCrossRefGoogle Scholar
  75. Randall ME et al (2006) Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44PubMedCrossRefGoogle Scholar
  76. Rao GG et al (2005) Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 96:168–172PubMedCrossRefGoogle Scholar
  77. Roberts KB et al (2000) Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 90:206–223PubMedCrossRefGoogle Scholar
  78. Rose P et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153PubMedCrossRefGoogle Scholar
  79. Ryu HS et al (2000) High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76:320–325PubMedCrossRefGoogle Scholar
  80. Stokes Z et al (2005) Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecol Oncol 97:790–795PubMedCrossRefGoogle Scholar
  81. Tannock IF et al (2005) The basic science of oncology, 4th edn. McGraw-Hill, Toronto, p 555Google Scholar
  82. Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, Hsueh S. (1997) A randomized trial on concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Gynecol Oncol. 66(1):52–58PubMedCrossRefGoogle Scholar
  83. Vaupel P (2004) Tumor microenvironmental physiology and its implication for radiation oncology. Semin Radiat Oncol 14:198–206PubMedCrossRefGoogle Scholar
  84. Vrdoljak E et al (2005) Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study. Int J Radiat Oncol Biol Phys 61:824–829PubMedCrossRefGoogle Scholar
  85. Whitney CW et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–1348PubMedGoogle Scholar
  86. Wiig H, Rubin K, Reed RK (2003) New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol Scand 47:111–121PubMedCrossRefGoogle Scholar
  87. Willett CG et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRefGoogle Scholar
  88. Winter WE et al (2004) Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 94:495–501PubMedCrossRefGoogle Scholar
  89. Wong LC, Ngan HY, Cheung AN, Cheng DK, Ng TY, Choy DT. (1999) Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol. 17(7):2055–2060PubMedGoogle Scholar
  90. Zarba JJ et al (2003) A phase I–II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 14:1285–1290PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Anthony W. Fyles
    • 1
  • Michael Milosevic
    • 1
  • Amit Oza
    • 2
  1. 1.Department of Radiation OncologyPrincess Margaret HospitalTorontoCanada
  2. 2.Department of Medical Oncology and HaematologyPrincess Margaret HospitalTorontoCanada

Personalised recommendations